PTC Therapeutics, Inc. (PTCT) stock
PTCTNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Oct 29, 2026Score 5/3031% above fair value
$63.49+0.13 (+0.21%)
Close on Nov 13, 2026Market cap $5.30BP/E –Yield –
PTC Therapeutics cash
Cash and short-term investments held at the end of each period.
PTC Therapeutics's cash was $2.13B at Sep 30, 2026. For fiscal 2025 it was $1.95B, up 68.4% from the year before. Over ten years it grew 19.1% a year on average. The highest annual figure on record is $1.95B in fiscal 2025.
Annual cash
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.95B | +68.4% |
| FY2024 | Dec 31, 2024 | $1.16B | +29.4% |
| FY2023 | Dec 31, 2023 | $893.02M | +109.2% |
| FY2022 | Dec 31, 2022 | $426.80M | -45.3% |
| FY2021 | Dec 31, 2021 | $780.88M | -29.7% |
| FY2020 | Dec 31, 2020 | $1.11B | +60.1% |
| FY2019 | Dec 31, 2019 | $694.06M | +205.0% |
| FY2018 | Dec 31, 2018 | $227.59M | +19.0% |
| FY2017 | Dec 31, 2017 | $191.25M | -17.4% |
| FY2016 | Dec 31, 2016 | $231.67M | -31.6% |
| FY2015 | Dec 31, 2015 | $338.93M | +7.5% |
| FY2014 | Dec 31, 2014 | $315.24M | +121.3% |
| FY2013 | Dec 31, 2013 | $142.47M | +5126.2% |
| FY2012 | Dec 31, 2012 | $2.73M | -90.4% |
| FY2011 | Dec 31, 2011 | $28.43M | -0.8% |
| FY2010 | Dec 31, 2010 | $28.67M | – |
Quarterly cash
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | $2.13B | +25.1% |
| Q2 FY2026 | Jun 30, 2026 | $2.23B | +11.2% |
| Q1 FY2026 | Mar 31, 2026 | $1.89B | -7.4% |
| Q4 FY2025 | Dec 31, 2025 | $1.95B | +68.4% |
| Q3 FY2025 | Sep 30, 2025 | $1.70B | +65.7% |
| Q2 FY2025 | Jun 30, 2025 | $2.00B | +81.1% |
| Q1 FY2025 | Mar 31, 2025 | $2.04B | +126.7% |
| Q4 FY2024 | Dec 31, 2024 | $1.16B | +29.4% |
| Q3 FY2024 | Sep 30, 2024 | $1.03B | +230.2% |
| Q2 FY2024 | Jun 30, 2024 | $1.11B | +212.7% |
| Q1 FY2024 | Mar 31, 2024 | $901.08M | +155.7% |
| Q4 FY2023 | Dec 31, 2023 | $893.02M | +109.2% |
| Q3 FY2023 | Sep 30, 2023 | $311.06M | +2.1% |
| Q2 FY2023 | Jun 30, 2023 | $354.05M | -32.1% |
| Q1 FY2023 | Mar 31, 2023 | $352.40M | -40.8% |
| Q4 FY2022 | Dec 31, 2022 | $426.80M | -45.3% |
| Q3 FY2022 | Sep 30, 2022 | $304.52M | -65.2% |
| Q2 FY2022 | Jun 30, 2022 | $521.63M | -45.4% |
| Q1 FY2022 | Mar 31, 2022 | $595.29M | -40.2% |
| Q4 FY2021 | Dec 31, 2021 | $780.88M | -29.7% |
| Q3 FY2021 | Sep 30, 2021 | $875.44M | -23.8% |
| Q2 FY2021 | Jun 30, 2021 | $954.58M | +88.5% |
| Q1 FY2021 | Mar 31, 2021 | $995.91M | +65.1% |
| Q4 FY2020 | Dec 31, 2020 | $1.11B | +60.1% |
| Q3 FY2020 | Sep 30, 2020 | $1.15B | +60.4% |
| Q2 FY2020 | Jun 30, 2020 | $506.39M | +39.3% |
| Q1 FY2020 | Mar 31, 2020 | $603.36M | +48.2% |
| Q4 FY2019 | Dec 31, 2019 | $694.06M | +205.0% |
| Q3 FY2019 | Sep 30, 2019 | $716.15M | +187.1% |
| Q2 FY2019 | Jun 30, 2019 | $363.54M | +22.8% |
| Q1 FY2019 | Mar 31, 2019 | $407.16M | +128.4% |
| Q4 FY2018 | Dec 31, 2018 | $227.59M | +19.0% |
| Q3 FY2018 | Sep 30, 2018 | $249.40M | +47.3% |
| Q2 FY2018 | Jun 30, 2018 | $296.11M | +63.5% |
| Q1 FY2018 | Mar 31, 2018 | $178.27M | -12.0% |
| Q4 FY2017 | Dec 31, 2017 | $191.25M | -17.4% |
| Q3 FY2017 | Sep 30, 2017 | $169.31M | – |
| Q2 FY2017 | Jun 30, 2017 | $181.07M | – |
| Q1 FY2017 | Mar 31, 2017 | $202.58M | – |
| Q4 FY2016 | Dec 31, 2016 | $231.67M | – |
See a number that looks wrong?